<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774107</url>
  </required_header>
  <id_info>
    <org_study_id>A20-102</org_study_id>
    <nct_id>NCT04774107</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic HCV Genotype 2 Infection</brief_title>
  <official_title>An Open-label Study to Assess the Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis With HCV Genotype 2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaEssentia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaEssentia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To determine the P1101 PK profile at the single dose of 400 μg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary Objective:&#xD;
&#xD;
      To determine the safety and immunogenicity of P1101 400 μg SC single dose + Ribavirin&#xD;
      800-1400 mg PO daily.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of P1101 in the blood stream</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>The measurement of P1101 levels in the blood stream over time. The sampling time points are 0 hour before the first dose, 24±4 hours, 48±4 hours, 72±4 hours, 96±4 hours, 168±4 hours, 216±4 hours, 264±4 hours and 336±4 hours after first dose. PK sampling at 504±4 hours and 672±4 hours after first dose are optional.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>To evaluate the safety of P1101 by the proportion of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Laboratory Assessments</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>To evaluate the safety of P1101 by the proportion of abnormal laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive anti-drug antibodies</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>To evaluate the positive anti-drug antibodies of P1101 by the proportion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive neutralizing antibody</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>To evaluate the positive neutralizing antibody of P1101 by the proportion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>P1101 + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>P1101 400 µg SC Ribavirin 800-1400 mg PO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P1101 + Ribavirin</intervention_name>
    <description>P1101 400 µg SC</description>
    <arm_group_label>P1101 + Ribavirin</arm_group_label>
    <other_name>Ropeginterferon alfa-2b</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults ≥18 years of age (or other age required by local regulations)&#xD;
&#xD;
          2. Confirmed diagnosis of chronic hepatitis with HCV genotype 2 infection.&#xD;
&#xD;
          3. Compensated liver disease defined by normal, normal albumin, normal INR&#xD;
&#xD;
          4. Interferon treatment naïve: never received any interferon.&#xD;
&#xD;
          5. No other known form of chronic liver disease apart from chronic hepatitis C infection.&#xD;
&#xD;
          6. Hemoglobin 12 g/dL in men or 11 g/dL in women, WBC count 3,000/mm3, ANC 1,500/mm3,&#xD;
             platelet count 90,000/mm3; and estimated glomerular filtration rate &gt;60 mL/min.&#xD;
&#xD;
          7. Female and male subjects, and their partners of reproductive potential using effective&#xD;
             means of contraception during the whole trial period.&#xD;
&#xD;
          8. Be able to attend all scheduled visits and to comply with all study procedures;&#xD;
&#xD;
          9. Be able to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Decompensated liver disease.&#xD;
&#xD;
          2. Clinically significant illness or surgery.&#xD;
&#xD;
          3. Any reason which, in the opinion of the investigator, would prevent the subject from&#xD;
             participating in the study.&#xD;
&#xD;
          4. Positive test for HBsAg or HIV at screening.&#xD;
&#xD;
          5. Clinically significant abnormal vital signs.&#xD;
&#xD;
          6. Evidence of severe retinopathy by fundoscopy except age-related macular degeneration.&#xD;
&#xD;
          7. Significant alcohol or illicit drug abuse within one year prior to the screening visit&#xD;
             or refusal to abstain from excessive alcohol consumption as defined above or illicit&#xD;
             drugs throughout the study.&#xD;
&#xD;
          8. Pregnant or breast feeding female subjects.&#xD;
&#xD;
          9. Therapy with any systemic anti-viral, anti-neoplastic, and immunomodulatory treatment.&#xD;
&#xD;
         10. Use of an investigational drug or participation in an investigational drug.&#xD;
&#xD;
         11. Known clinically significant presence of any gastrointestinal pathology, clinically&#xD;
             significant unresolved gastrointestinal symptoms, clinically significant liver or&#xD;
             clinically significant kidney disease, or other conditions known to interfere with the&#xD;
             absorption, distribution, metabolism, or excretion of the drug.&#xD;
&#xD;
         12. Clinically significant presence of depression determined by investigators.&#xD;
&#xD;
         13. Clinically significant presence of severe neurological disorders.&#xD;
&#xD;
         14. Clinically significant presence of severe cardiovascular conditions and severe&#xD;
             pulmonary conditions, uncontrolled immunologic, uncontrolled autoimmune, uncontrolled&#xD;
             endocrine, uncontrolled metabolic, haematological, severe coagulation disorders or&#xD;
             severe blood dyscrasias or other severe uncontrolled systemic disease.&#xD;
&#xD;
         15. A depot injection or an implant of any drug within 3 months prior to administration of&#xD;
             study medication, other than contraception or hyaluronic acid injections in joints for&#xD;
             osteoarthritis;&#xD;
&#xD;
         16. Body organ transplant and are taking immunosuppressants;&#xD;
&#xD;
         17. History of malignant disease, including solid tumors and hematologic malignancies.&#xD;
             However, subjects who are cancer survivors not on maintenance therapy and who had no&#xD;
             malignant diseases history within the past 5 years could be recruited.&#xD;
&#xD;
         18. History of or ongoing opportunistic infection.&#xD;
&#xD;
         19. Serious local infection or systemic infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huang Yi-Wen, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>PharmaEssentia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lai Candy</last_name>
    <phone>0226557688</phone>
    <phone_ext>1364</phone_ext>
    <email>candy_lai@pharmaessentia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chia-Yi Christian Hospital</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Martin De Porres Hospital</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Kaohsiung Branch</name>
      <address>
        <city>Kaohsiung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chi Mei Hospital, Liouying</name>
      <address>
        <city>Tainan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center</name>
      <address>
        <city>Tainan City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taitung Mackay Memorial Hospital</name>
      <address>
        <city>Taitung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>P1101</keyword>
  <keyword>HCV GT2</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>PK</keyword>
  <keyword>Hepatitis C, Chronic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

